Leslie Smetzer

1.1k total citations
14 papers, 896 citations indexed

About

Leslie Smetzer is a scholar working on Oncology, Molecular Biology and Pharmacology. According to data from OpenAlex, Leslie Smetzer has authored 14 papers receiving a total of 896 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 8 papers in Molecular Biology and 2 papers in Pharmacology. Recurrent topics in Leslie Smetzer's work include Colorectal Cancer Treatments and Studies (4 papers), Cancer Treatment and Pharmacology (4 papers) and Melanoma and MAPK Pathways (2 papers). Leslie Smetzer is often cited by papers focused on Colorectal Cancer Treatments and Studies (4 papers), Cancer Treatment and Pharmacology (4 papers) and Melanoma and MAPK Pathways (2 papers). Leslie Smetzer collaborates with scholars based in United States, Switzerland and China. Leslie Smetzer's co-authors include Daniel D. Von Hoff, Anthony W. Tolcher, Amita Patnaik, Lon Smith, Eric K. Rowinsky, Drew Rasco, G. Mangold, Shelly Gunn, Kyriakos P. Papadopoulos and Theresa A. Mays and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Annals of Oncology.

In The Last Decade

Leslie Smetzer

14 papers receiving 873 citations

Peers

Leslie Smetzer

ONCOL

PRM

PFM

Arris J. Henderson United States

Shane K. Green Canada

Sujatha Jagadeeswaran United States

Donna Voeller United States

Raymond Wadlow United States

Josep Lluís Parra United Kingdom

Anne Keating United States

Ainura Kyshtoobayeva United States

Ben Allal France

Carla Kurkjian United States

Arris J. Henderson United States

Leslie Smetzer

454 ×0.8

424 ×0.9

ONCOL

186 ×1.2

128 ×0.9

PRM

111 ×1.2

PFM

Citations per year, relative to Leslie Smetzer Leslie Smetzer (= 1×) peers Arris J. Henderson

Countries citing papers authored by Leslie Smetzer

Since Specialization

Citations

This map shows the geographic impact of Leslie Smetzer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leslie Smetzer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leslie Smetzer more than expected).

Fields of papers citing papers by Leslie Smetzer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leslie Smetzer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leslie Smetzer. The network helps show where Leslie Smetzer may publish in the future.

Co-authorship network of co-authors of Leslie Smetzer

This figure shows the co-authorship network connecting the top 25 collaborators of Leslie Smetzer. A scholar is included among the top collaborators of Leslie Smetzer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leslie Smetzer. Leslie Smetzer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Shimizu, Toshio, Anthony W. Tolcher, Kyriakos P. Papadopoulos, et al.. (2012). The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer. Clinical Cancer Research. 18(8). 2316–2325. 352 indexed citations

Shimizu, Takashi, A. W. Tolcher, Kyriakos P. Papadopoulos, et al.. (2011). The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in first-in-human phase I study: The START Center experience.. Journal of Clinical Oncology. 29(15_suppl). 2502–2502. 4 indexed citations

Tolcher, Anthony W., Desirée Hao, Johann S. de Bono, et al.. (2006). Phase I, Pharmacokinetic, and Pharmacodynamic Study of Intravenously Administered Ad5CMV-p53, an Adenoviral Vector Containing the Wild-Type p53 Gene, in Patients With Advanced Cancer. Journal of Clinical Oncology. 24(13). 2052–2058. 34 indexed citations

Tolcher, Anthony W., John G. Kuhn, Garry Schwartz, et al.. (2004). A Phase I Pharmacokinetic and Biological Correlative Study of Oblimersen Sodium (Genasense, G3139), an Antisense Oligonucleotide to the Bcl-2 mRNA, and of Docetaxel in Patients with Hormone-Refractory Prostate Cancer. Clinical Cancer Research. 10(15). 5048–5057. 61 indexed citations

Garrison, Mitchell, Lisa A. Hammond, Charles E. Geyer, et al.. (2003). A Phase I and pharmocokinetic study of exatecan mesylate administered as a protracted 21-day infusion in patients with advanced solid malignancies.. PubMed. 9(7). 2527–37. 14 indexed citations

Forouzesh, Bahram, Chris H. Takimoto, Andrew Goetz, et al.. (2003). A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.. PubMed. 9(15). 5540–9. 12 indexed citations

Schwartz, Gary K., Thomas R. Johnson, Aaron S. Goetz, et al.. (2001). A phase I and pharmacokinetic study of 1843U89, a noncompetitive inhibitor of thymidylate synthase, in patients with advanced solid malignancies.. PubMed. 7(7). 1901–11. 11 indexed citations

Rowinsky, Eric K., Thomas R. Johnson, Charles E. Geyer, et al.. (2000). DX-8951f, a Hexacyclic Camptothecin Analog, on a Daily-Times-Five Schedule: A Phase I and Pharmacokinetic Study in Patients With Advanced Solid Malignancies. Journal of Clinical Oncology. 18(17). 3151–3163. 37 indexed citations

Britten, Carolyn D., Eric K. Rowinsky, Sharyn D. Baker, et al.. (2000). A phase I and pharmacokinetic study of the mitochondrial-specific rhodacyanine dye analog MKT 077.. PubMed. 6(1). 42–9. 88 indexed citations

10.

Rowinsky, Eric K., Rachel Humphrey, Lisa A. Hammond, et al.. (2000). Phase I and Pharmacologic Study of the Specific Matrix Metalloproteinase Inhibitor BAY 12-9566 on a Protracted Oral Daily Dosing Schedule in Patients With Solid Malignancies. Journal of Clinical Oncology. 18(1). 178–178. 72 indexed citations

11.

Petit, Thierry, Howard A. Burris, Peter M. Ravdin, et al.. (1999). A phase I study of docetaxel and 5-fluorouraciI in patients with advanced solid malignancies. Annals of Oncology. 10(2). 223–230. 13 indexed citations

12.

Schilsky, Richard L., John Hohneker, Mark J. Ratain, et al.. (1998). Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer.. Journal of Clinical Oncology. 16(4). 1450–1457. 91 indexed citations

13.

Eckhardt, S. Gail, Howard A. Burris, John R. Eckardt, et al.. (1996). A phase I clinical and pharmacokinetic study of the angiogenesis inhibitor, tecogalan sodium. Annals of Oncology. 7(5). 491–496. 34 indexed citations

14.

Bedikian, Agop Y., Geoffrey R. Weiss, Sewa S. Legha, et al.. (1995). Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy.. Journal of Clinical Oncology. 13(12). 2895–2899. 73 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact